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Abstract
Due to a number of distinct advantages resulting from the relatively low energy
gamma ray spectrum of Yb-169, various designs of Yb-169 sources have been devel-
oped over the years for brachytherapy applications. Lately, Yb-169 has also been sug-
gested as an effective and practical radioisotope option for a novel radiation
treatment approach often known as gold nanoparticle-aided radiation therapy (GNRT).
In a recently published study, the current investigators used the Monte Carlo N-Parti-
cle Version 5 (MCNP5) code to design a novel titanium-encapsulated Yb-169 source
optimized for GNRT applications. In this study, the original MC source model was
modiﬁed to accurately match the speciﬁcations of the manufactured Yb-169 source.
The modiﬁed MC model was then used to obtain a complete set of the AAPM TG-43
parameters for the new titanium-encapsulated Yb-169 source. The MC-calculated
dose rate constant for this titanium-encapsulated Yb-169 source was
1.19  0.03 cGy  h1  U1, indicating no signiﬁcant change from the values reported
for stainless steel-encapsulated Yb-169 sources. The source anisotropy and radial
dose function for the new source were also found similar to those reported for the
stainless steel-encapsulated Yb-169 sources. The current results suggest that the use
of titanium, instead of stainless steel, to encapsulate the Yb-169 core would not lead
to any major change in the dosimetric characteristics of the Yb-169 source. The results
also show that the titanium encapsulation of the Yb-169 source could be accom-
plished while meeting the design goals as described in the current investigators’ pub-
lished MC optimization study for GNRT applications.
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1 | INTRODUCTION
Over the years, various designs of Yb-169 sources have been
described in the published literature.1–13 As summarized previ-
ously,13 the relatively low energy photon spectrum of Yb-169 would
provide multiple advantages including the possibility of in vivo shield-
ing of essential organs and tissues via shielded applicator (e.g., using
0.5–1.0 mm thick lead foils in the applicator system to reduce blad-
der and rectal doses in gynecological malignancies3), reduced radia-
tion exposure to personnel, simpliﬁed high dose rate (HDR) room
shielding, streamlined after-loading units, and overall reduced
costs.1–4,7,9–12 Additionally, Yb-169 has been suggested as an almost
ideal radioisotope for the brachytherapy implementation of so-called
gold nanoparticle-aided radiation therapy (GNRT),13,14 because its
gamma ray spectrum (average energy of 93 keV just above the
K-absorption edge of gold) can lead to more advantageous (e.g., larger
or/and more uniform) dose enhancement characteristics with gold
nanoparticles (GNPs) than other radioisotopes being used for
brachytherapy purposes (e.g., Ir-192, I-125, Pd-103, etc.). To follow-up
on this suggestion, we designed a new titanium-encapsulated Yb-169
source optimized for GNRT applications,13 based on our Monte Carlo
(MC) investigation of the effects of the Yb-169 source encapsulation
on the photon spectra, and more importantly the secondary electron
spectra that are directly responsible for the dose enhancement charac-
teristics for a given concentration of GNPs. After our initial MC source
design study,13 we proceeded to produce novel titanium-encapsulated
Yb-169 sources in collaboration with a source manufacturer (Source
Production & Equipment Co., Inc., St. Rose, LA, USA).
In the current MC study, we determined a complete set of
brachytherapy dosimetry parameters for the aforementioned tita-
nium-encapsulated Yb-169 source model, following the American
Association of Physicists in Medicine (AAPM) Task Group 43 (TG-
43) formalism.15,16 The key results from the current investigation
were compared with those from the previous investigations of vari-
ous Yb-169 source models, in light of GNRT as well as general
brachytherapy applications.
2 | METHODS
2.A | Source design
As described in our previous publication,13 the new Yb-169 source opti-
mized for GNRT applications was designed similar to a previously investi-
gated HDR Yb-169 source,7,12,17 with the exception of the encapsulation
material (i.e., titanium vs. stainless steel). While its speciﬁc design was
slightly different from that described in our previous publication,13 the
new Yb-169 source manufactured from this investigation maintained the
key features of our original source design, most notably the titanium
encapsulation as compared to a more conventional stainless steel encap-
sulation. As depicted in Fig. 1, the new Yb-169 seed source had an active
Ytterbium core (3.5 mm in length, 0.6 mm in diameter, and
7.0 mg mm3 in density) encapsulated by American Society for Testing
and Materials (ASTM) grade 2 titanium (4.54 mg mm3 in density). This
source had an air gap between the active Ytterbium core and titanium
encapsulation, which was included in ourMCmodel (Fig. 1) following the
speciﬁcations provided by the source manufacturer. It should be noted
that, while intended for eventual HDR applications, Yb-169 sources pro-
duced during the current investigation had their activities on the order of
10 mCi for the ease of handling and testing.
2.B | Monte Carlo calculations of TG-43 parameters
The MC radiation transport code, Monte Carlo N-Particle Version 5
(MCNP5), was used to compute all the necessary quantities to char-
acterize the Yb-169 source as deﬁned by TG-43. The source and
encapsulation geometry were modeled exactly as shown in Fig. 1.
The active region of the source was modeled with a uniform activity
distribution. Table 1 shows the Yb-169 photon spectrum used for
the current MC study excluding all photons with intensity lower than
0.1% and energy lower than 5 keV as speciﬁed in TG-43.15,16 Two
different MCNP models were developed to compute all TG-43
parameters: SK the air-kerma strength of the source (lGym2/h), Λ
the dose-rate constant in water (1/m2), G r; hð Þ the geometry function
(1/m2), gL rð Þ the radial dose function, F r; hð Þ the anisotropy function.
F I G . 1 . MCNP5 model of the manufactured titanium-encapsulated
169Yb source per the detailed speciﬁcations from the source
manufacturer (Source Production & Equipment Co., Inc., St. Rose,
LA). As shown, an active Ytterbium core is 3.5 mm in length and
0.6 mm in diameter. For the anisotropy data, h = 0 is corresponding
to the vertical axis of the source in the negative (downward)
direction in the diagram. Figure is drawn to scale.
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The air-kerma strength Sk was calculated with the Yb-169 source
centered in a 130 cm radius spherical phantom in vacuo. The air-
kerma rate was determined at the reference point ho = 90
o at a dis-
tance d = 100 cm using the MCNP5 energy deposition F6 tally with
units of MeVg1photon1. This region was deﬁned by ﬁrst delineat-
ing the region at d = 100 cm from the center of the source by deﬁn-
ing two concentric spheres with radii of 97.5 cm and 102.5 cm. The
angular constraint of ho = 90
o was deﬁned by using two cones with
vertex angles of h = 88o one aligned with the +z-axis and the other
aligned with the –z-axis. This deﬁned a 5 cm ring tally centered at
d = 100 cm with ho = 90
o  2o. The MCNP output was the air-
kerma per source photon KMCð Þ in units of MeV  g1  photon1.
The air-kerma rate was then calculated from KMC and converted to
units of cGy  mCi1  h1 by:
_K d; hð Þ ¼ KMC  Ic  2:134 103 cGymCi  h (1)
where Ic is the total number of photons per disintegration of the
source. The air-kerma rate may also be written in terms of the unit
U (cGy  cm2  h1) as speciﬁed in TG-43.15,16
The dose distribution surrounding the source was computed by
simulating the source centered in a spherical water phantom with a
radius of 50 cm, an appropriate size to approximate full-scatter
conditions of a semi-inﬁnite water phantom. An array of tally regions
was modeled to collect the dose at radial distances of 0.5 cm and 1–
10 cm in 1 cm steps and at angles between h = 0o and h = 180o in
10o steps. This was accomplished by generating spherical shells with
mean radii at the desired radial distance (i.e., 0.5 cm and 1–10 cm in
1 cm steps). The thickness of each shell was calculated to be as thin as
possible to appropriately approximate the detection region while maxi-
mizing collection efﬁciency during the MC simulation. The criteria
were developed by Luxton et al.18 and compare the factor
RV ¼ R31 þ R32=2
 1
3 that subdivides each shell bounded by the inner
radius R1 and outer radius R2 into smaller shells of equal volume, with
the mean radius of the shell RM = (R1 + R2)/2. The calculated dose for
a shell approximates the dose at that mean radius of the shell only if
the two factors differ by less than 1%, i.e.,
 RV=RMð Þ2  1
\0:01.
The angular dependence of each tally region was deﬁned by
using concentric cones about the +z-axis and –z-axis to restrict col-
lection along the desired angle from h = 0o to h = 180o in 10o steps.
For the h = 00 region, a cone along the –z-axis with vertex angle of
2o deﬁned the h = 0o region; a similar cone along the +z-axis deﬁned
h = 180o. The regions between 10o and 170o are deﬁned by concen-
tric cones centered at the desired angle with an angular opening
 4o, e.g., for the h = 10o two concentric cones centered along the
–z-axis with vertex angles of 8o and 12o deﬁned the desired tally
region. The same method was used to deﬁne all of the angles and
using concentric cones with the appropriate vertex angles to deﬁne
each region in 10o (i.e., 8o;12o;18o;22o;28o;32o; . . .Þ. The result is a





0.5 1 2 3 4 5 6 7 8 9 10
0 4.558 1.032 0.252 0.111 0.063 0.040 0.028 0.020 0.016 0.012 0.010
10 4.530 1.030 0.252 0.111 0.063 0.040 0.028 0.020 0.016 0.012 0.010
20 4.450 1.026 0.252 0.111 0.063 0.040 0.028 0.020 0.016 0.012 0.010
30 4.337 1.021 0.251 0.111 0.063 0.040 0.028 0.020 0.016 0.012 0.010
40 4.212 1.014 0.251 0.111 0.063 0.040 0.028 0.020 0.016 0.012 0.010
50 4.092 1.006 0.250 0.111 0.063 0.040 0.028 0.020 0.016 0.012 0.010
60 3.989 1.000 0.250 0.111 0.062 0.040 0.028 0.020 0.016 0.012 0.010
70 3.912 0.995 0.250 0.111 0.062 0.040 0.028 0.020 0.016 0.012 0.010
80 3.864 0.991 0.249 0.111 0.062 0.040 0.028 0.020 0.016 0.012 0.010
90 3.848 0.990 0.249 0.111 0.062 0.040 0.028 0.020 0.016 0.012 0.010
TAB L E 1 Yb-169 photon spectrum including all photons with yields
greater than 0.1% and ignoring all dosimetrically irrelevant gamma
rays below 5 keV.
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series of ring tallies that collect the dose distribution surrounding
the source.
3 | RESULTS
MCNP5 calculations resulted in the air-kerma strength as
SK ¼ 1:15 0:03U mCi1 and the dose rate at the reference point
_D ro; hoð Þas 1:37 0:02cGy mCi1  h1. Accordingly, the dose-rate
constant was calculated as K ¼ 1:19 0:03cGy  h1  U1. This value
can be compared to other reported values for Yb-169 source models:
Λ = 1.210  0.050,11 Λ = 1.204  0.004,19 Λ = 1.19  0.03,7 Λ = 1.12
 0.04,12 Λ = 1.170  0.010, and Λ = 1.191  0.007 cGy  h1  U1.20
The geometry function GL r; hð Þ (Table 2) represents the effective
inverse-square correction based on the line-source approximation.
The function shows it effectively becomes point sources for r5cm:
The radial dose functions are shown in Table 3 and the ﬁt to 5th
order polynomial as speciﬁed in the updated report of TG-4315 is
shown in Fig. 2. Table 4 presents the values of 2D anisotropy func-
tion F r; hð Þ from the current study. Figure 3 shows a comparison of
the source anisotropy at r = 1.0 cm between the current titanium-
encapsulated Yb-169 source and a previously described stainless
steel encapsulated Yb-169 source.7
4 | DISCUSSION
In a previous study,13 we showed that titanium-encapsulation of
the Yb-169 core would allow more low energy photon being trans-
mitted through the source ﬁlter and, as a result, lead to an
increased dose enhancement during GNRT, compared to stainless
steel-encapsulation. Additionally, we pointed out that the increased
structural integrity of titanium over stainless steel might also pro-
vide the possibility to shrink the size of the source encapsulation,
thereby further improving the dose enhancement characteristics of
the source.13 Thus, we have focused our research effort on devel-
oping titanium-encapsulated Yb-169 sources, even though we also
demonstrated in the aforementioned study13 that even stainless
steel-encapsulated Yb-169 sources would be superior to more
popular Ir-192 sources, in terms of their dose enhancement
characteristics.
As noted above, our previous publication13 focused on describ-
ing our research methods and ﬁndings, speciﬁcally with regards to
the dose enhancement characteristics of Yb-169 sources. As a
result, there was a lack of coverage regarding more practical dosi-
metric issues such as the inﬂuence of titanium encapsulation on the
TG-43 parameters of Yb-169 sources, which also need to be investi-
gated in order to ensure the applicability of titanium-encapsulated
TAB L E 3 Radial dose function gL r; hð Þ values.
r (cm)
gL (r) for Ti design
0.5 0.951  0.027
1 1.000
2 1.077  0.030
3 1.129  0.032
4 1.161  0.033
5 1.172  0.033
6 1.168  0.033
7 1.150  0.032
8 1.124  0.032
9 1.091  0.031
10 1.051  0.030
F I G . 2 . Calculated radial dose function
for the current Yb-169 source and 5th
degree polynomial ﬁt along with
corresponding ﬁtting parameters.
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Yb-169 sources to GNRT as well as conventional brachytherapy
applications. Thus, this investigation was conducted to provide some
insight into such issues. For example, the dose rate constant for the
titanium-encapsulated Yb-169 source produced from this study was
found comparable to the values reported for various models of
stainless steel-encapsulated Yb-169 sources. Despite the differences
in ﬁltration due to different encapsulation designs and materials, the
source anisotropy and radial dose function for the new source were
also found similar to those reported for the conventional Yb-169
sources.
5 | CONCLUSIONS
In this study, the AAPM TG-43 brachytherapy dosimetry parameters
for a new titanium-encapsulated Yb-169 source were determined by
MC calculations. The current results suggested that the use of tita-
nium, instead of stainless steel, to encapsulate the Yb-169 core
would not lead to any major change in the dosimetric characteristics
of the Yb-169 source, while meeting the design goals as described in
the current investigators’ published MC optimization study for GNRT
applications.
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